NCT01673217.

Trial name or title	Decitabine, vaccine therapy, and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer
Methods	Uncontrolled phase I
Participants	18 women with relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer who are to receive liposomal doxorubicin as salvage therapy for recurrent disease
Interventions	Intravenous decitabine, intravenous liposomal doxorubicin, subcutaneous NY‐ESO‐1 peptide vaccine in Montanide ISA‐51, subcutaneous GM‐CSF
Outcomes	Adverse events Immune responses Survival
Starting date	April 2009
Contact information
Notes	Study completed June 2013; no publication available